OncoMatch/Clinical Trials/NCT07874581
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
Official title: Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Patients With Relapsed Small Cell Lung Cancer: A Single-Center, Single-Arm, Exploratory Study
Is NCT07874581 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies MRG003 (Becotatug Vedotin) for relapsed small cell lung cancer (sclc).
Treatment: MRG003 (Becotatug Vedotin) — This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer. Eligible patients receive becotatug vedotin at a dose of 2.3 mg/kg administered by intravenous infusion once every 21 days until disease progression or unacceptable toxicity. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment; at least one measurable lesion according to RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anticancer therapy
Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment
Lab requirements
Blood counts
Adequate organ and bone marrow function
Kidney function
Adequate organ and bone marrow function
Liver function
Adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07874581 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anticancer therapy.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages